Your browser doesn't support javascript.
loading
SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy
Lova Sun; Sanjna Surya; Noah G.; Anh N. Le; Gregory Kelly; Olutosin Owoyemi; Heena Desai; Cathy Zheng; Shannon DeLuca; Madeline L. Good; Jasmin Hussain; Seth D. Jeffries; Yolanda R. Kry; Emily M. Kugler; Maikel Mansour; John Ndicu; AnnaClaire Osei-Akoto; Timothy Prior; Stacy L. Pundock; Lisa A. Varughese; JoEllen Weaver; Abigail Doucette; Scott Dudek; Shefali Setia Verma; Sigrid Gouma; Madison E. Weirick; Christopher M. McAllister; Erin Bange; Peter Gabriel; Marylyn Ritchie; Daniel J. Rader; Robert H. Vonderheide; Lynn M Schuchter; Anurag Verma; Ivan Maillard; Ronac Mamtani; Scott E. Hensley; Robert Gross; E. Paul Wileyto; Alexander C. Huang; Kara N. Maxwell; Angela DeMichele.
Afiliación
  • Lova Sun; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Sanjna Surya; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Noah G.; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Anh N. Le; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Gregory Kelly; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Olutosin Owoyemi; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Heena Desai; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Cathy Zheng; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Shannon DeLuca; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Madeline L. Good; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Jasmin Hussain; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Seth D. Jeffries; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Yolanda R. Kry; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Emily M. Kugler; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Maikel Mansour; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • John Ndicu; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • AnnaClaire Osei-Akoto; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Timothy Prior; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Stacy L. Pundock; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Lisa A. Varughese; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • JoEllen Weaver; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Abigail Doucette; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Scott Dudek; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Shefali Setia Verma; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Sigrid Gouma; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104
  • Madison E. Weirick; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104
  • Christopher M. McAllister; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104
  • Erin Bange; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Peter Gabriel; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Marylyn Ritchie; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Daniel J. Rader; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Robert H. Vonderheide; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Lynn M Schuchter; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Anurag Verma; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Ivan Maillard; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Ronac Mamtani; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Scott E. Hensley; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, 19104
  • Robert Gross; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • E. Paul Wileyto; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Alexander C. Huang; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Kara N. Maxwell; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
  • Angela DeMichele; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21249810
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.
Licencia
cc_no
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint